| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6419958 | OSMOTICA PHARM US | Extended release formulation of venlafaxine hydrochloride |
Mar, 2017
(7 years ago) | |
| US6403120 | OSMOTICA PHARM US | Extended release formulation of venlafaxine hydrochloride |
Mar, 2017
(7 years ago) | |
Venlafaxine Hydrochloride is owned by Osmotica Pharm Us.
Venlafaxine Hydrochloride contains Venlafaxine Hydrochloride.
Venlafaxine Hydrochloride has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Venlafaxine Hydrochloride are:
- US6419958
- US6403120
Venlafaxine Hydrochloride was authorised for market use on 20 May, 2008.
Venlafaxine Hydrochloride is available in tablet, extended release;oral dosage forms.
Venlafaxine Hydrochloride can be used as treatment of social anxiety disorder, treatment of major depressive disorder (mdd).
The generics of Venlafaxine Hydrochloride are possible to be released after 20 March, 2017.
Drugs and Companies using VENLAFAXINE HYDROCHLORIDE ingredient
Market Authorisation Date: 20 May, 2008
Treatment: Treatment of major depressive disorder (mdd); Treatment of social anxiety disorder
Dosage: TABLET, EXTENDED RELEASE;ORAL
VENLAFAXINE HYDROCHLORIDE family patents
